The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ioannides, C. G.
Right arrow Articles by Finn, O. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ioannides, C. G.
Right arrow Articles by Finn, O. J.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Ovarian Cancer

The Journal of Immunology, Vol 151, Issue 7 3693-3703, Copyright © 1993 by American Association of Immunologists

ARTICLES

Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides

CG Ioannides, B Fisk, KR Jerome, T Irimura, JT Wharton and OJ Finn
Department of Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030.

CTL isolated from tumor infiltrating lymphocytes/tumor associated lymphocytes (TAL) infiltrating ovarian tumors have been demonstrated to mediate lysis of tumor targets after in vitro culture. These effector cells are of particular interest as cellular probes to detect and define human tumor Ag and epitopes that stimulate cellular immunity to human tumors. Polymorphic epithelial mucin (PEM) core peptides are potential candidates as tumor specific Ag because of their preferential expression on epithelial tumors. We report here that ovarian CTL-TAL can recognize mucin (Muc-1) core peptide of PEM. Several ovarian CTL- TAL lines were developed that recognized in a non-MHC restricted fashion an Muc-1+ ovarian tumor, but not Muc-1-tumor. To define the specificity of these CTL-TAL and exclude cross-reactivity with other potential Ag, cytotoxicity experiments were performed using as targets EBV-transformed cell lines with an expression construct containing the Muc.1 cDNA. These ovarian CTL-TAL lysed mucin core-peptide transfected cells but not targets transfected with an expression construct containing a mucin frame-shift mutant cDNA as control. In addition, targets pulsed with short synthetic peptides composed of amino acids 1- 14 of the Muc 1 core peptide repeat were also lysed by the same CTL- TAL. This lysis was inhibited by the mAb SM3 that recognize an epitope on the mucin core peptide. These results, which are a demonstration of a specific Ag recognized by ovarian CTL-TAL, may be of interest for specific immunotherapy of ovarian cancer.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
P. Mukherjee, G. D. Basu, T. L. Tinder, D. B. Subramani, J. M. Bradley, M. Arefayene, T. Skaar, and G. De Petris
Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition
J. Immunol., January 1, 2009; 182(1): 216 - 224.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. L. Tinder, D. B. Subramani, G. D. Basu, J. M. Bradley, J. Schettini, A. Million, T. Skaar, and P. Mukherjee
MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma
J. Immunol., September 1, 2008; 181(5): 3116 - 3125.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Gulley, P. M. Arlen, A. Bastian, S. Morin, J. Marte, P. Beetham, K.-Y. Tsang, J. Yokokawa, J. W. Hodge, C. Menard, et al.
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
Clin. Cancer Res., May 1, 2005; 11(9): 3353 - 3362.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. M. Herbert, J. F. Grosso, M. Dorsey Jr., T. Fu, I. Keydar, M. A. Cejas, D. H. Wreschner, N. Smorodinski, and D. M. Lopez
A Unique Mucin Immunoenhancing Peptide with Antitumor Properties
Cancer Res., November 1, 2004; 64(21): 8077 - 8084.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K.-Y. Tsang, C. Palena, J. Gulley, P. Arlen, and J. Schlom
A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1
Clin. Cancer Res., March 15, 2004; 10(6): 2139 - 2149.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
Y. Xu, S. J. Gendler, and A. Franco
Designer Glycopeptides for Cytotoxic T Cell-based Elimination of Carcinomas
J. Exp. Med., March 1, 2004; 199(5): 707 - 716.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. J. Wajchman, C. W. Pierce, V. A. Varma, M. M. Issa, J. Petros, and K. E. Dombrowski
Ex Vivo Expansion of CD8+CD56+ and CD8+CD56- Natural Killer T Cells Specific for MUC1 Mucin
Cancer Res., February 1, 2004; 64(3): 1171 - 1180.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. K. Ko, K. Kawano, J. L. Murray, M. L. Disis, C. L. Efferson, H. M. Kuerer, G. E. Peoples, and C. G. Ioannides
Clinical Studies of Vaccines Targeting Breast Cancer
Clin. Cancer Res., August 1, 2003; 9(9): 3222 - 3234.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
V. Ramakrishna, M. M. Ross, M. Petersson, C. C. Gatlin, C. E. Lyons, C. L. Miller, H. E. Myers, M. McDaniel, L. R. Karns, R. Kiessling, et al.
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells
Int. Immunol., June 1, 2003; 15(6): 751 - 763.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Schlienger, C. S. Chu, E. Y. Woo, P. M. Rivers, A. J. Toll, B. Hudson, M. V. Maus, J. L. Riley, Y. Choi, G. Coukos, et al.
TRANCE- and CD40 Ligand-matured Dendritic Cells Reveal MHC Class I-restricted T Cells Specific for Autologous Tumor in Late-Stage Ovarian Cancer Patients
Clin. Cancer Res., April 1, 2003; 9(4): 1517 - 1527.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
K. Morikane, R. M. Tempero, C. L. Sivinski, S. Kitajima, S. J. Gendler, and M. A. Hollingsworth
Influence of organ site and tumor cell type on MUC1-specific tumor immunity
Int. Immunol., February 1, 2001; 13(2): 233 - 240.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Koido, M. Kashiwaba, D. Chen, S. Gendler, D. Kufe, and J. Gong
Induction of Antitumor Immunity by Vaccination of Dendritic Cells Transfected with MUC1 RNA
J. Immunol., November 15, 2000; 165(10): 5713 - 5719.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. P. Treon, P. Maimonis, D. Bua, G. Young, N. Raje, J. Mollick, D. Chauhan, Y.-T. Tai, T. Hideshima, Y. Shima, et al.
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma
Blood, November 1, 2000; 96(9): 3147 - 3153.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. M. Hiltbold, A. M. Vlad, P. Ciborowski, S. C. Watkins, and O. J. Finn
The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells
J. Immunol., October 1, 2000; 165(7): 3730 - 3741.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Mukherjee, A. R. Ginardi, C. S. Madsen, C. J. Sterner, M. C. Adriance, M. J. Tevethia, and S. J. Gendler
Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred
J. Immunol., September 15, 2000; 165(6): 3451 - 3460.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
S.-i. Takemura, R. Asano, K. Tsumoto, S. Ebara, N. Sakurai, Y. Katayose, H. Kodama, H. Yoshida, M. Suzuki, K. Imai, et al.
Construction of a diabody (small recombinant bispecific antibody) using a refolding system
Protein Eng. Des. Sel., August 1, 2000; 13(8): 583 - 588.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Karanikas, J. Lodding, V. C. Maino, and I. F. C. McKenzie
Flow Cytometric Measurement of Intracellular Cytokines Detects Immune Responses in MUC1 Immunotherapy
Clin. Cancer Res., March 1, 2000; 6(3): 829 - 837.
[Abstract] [Full Text]

Home page
 JCOHome page
S. von Mensdorff-Pouilly, A. A. Verstraeten, P. Kenemans, F. G. M. Snijdewint, A. Kok, G. J. Van Kamp, M. A. Paul, P. J. Van Diest, S. Meijer, and J. Hilgers
Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin
J. Clin. Oncol., February 1, 2000; 18(3): 574 - 574.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. Toura, T. Kawano, Y. Akutsu, T. Nakayama, T. Ochiai, and M. Taniguchi
Cutting Edge: Inhibition of Experimental Tumor Metastasis by Dendritic Cells Pulsed with {alpha}-Galactosylceramide
J. Immunol., September 1, 1999; 163(5): 2387 - 2391.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. M. Barratt-Boyes, A. Vlad, and O. J. Finn
Immunization of Chimpanzees with Tumor Antigen MUC1 Mucin Tandem Repeat Peptide Elicits Both Helper and CytotoxicT-Cell Responses
Clin. Cancer Res., July 1, 1999; 5(7): 1918 - 1924.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Brossart, K. S. Heinrich, G. Stuhler, L. Behnke, V. L. Reichardt, S. Stevanovic, A. Muhm, H.-G. Rammensee, L. Kanz, and W. Brugger
Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies
Blood, June 15, 1999; 93(12): 4309 - 4317.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. P. Treon, J. A. Mollick, M. Urashima, G. Teoh, D. Chauhan, A. Ogata, N. Raje, J. H.M. Hilgers, L. Nadler, A. R. Belch, et al.
Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone
Blood, February 15, 1999; 93(4): 1287 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. M. Tempero, M. L. VanLith, K. Morikane, G. J. Rowse, S. J. Gendler, and M. A. Hollingsworth
CD4+ Lymphocytes Provide MUC1-Specific Tumor Immunity In Vivo That Is Undetectable In Vitro and Is Absent in MUC1 Transgenic Mice
J. Immunol., November 15, 1998; 161(10): 5500 - 5506.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Magarian-Blander, P. Ciborowski, S. Hsia, S. C. Watkins, and O. J. Finn
Intercellular and Intracellular Events Following the MHC-Unrestricted TCR Recognition of a Tumor-Specific Peptide Epitope on the Epithelial Antigen MUC1
J. Immunol., April 1, 1998; 160(7): 3111 - 3120.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
L. B. E. Shields, C. Gercel-Taylor, C. M. Yashar, T. C. Wan, W. A. Katsanis, J. A. Spinnato, and D. D. Taylor
Induction of Immune Responses to Ovarian Tumor Antigens by Multiparity
Reproductive Sciences, November 1, 1997; 4(6): 298 - 304.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Gerloni, S. Xiong, S. Mukerjee, S. P. Schoenberger, M. Croft, and M. Zanetti
From the Cover: Functional cooperation between T helper cell determinants
PNAS, November 21, 2000; 97(24): 13269 - 13274.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.